Amgen Launches Amgevita (biosimilar, adalimumab) for the Treatment of Inflammatory Diseases in Brazil

 Amgen Launches Amgevita (biosimilar, adalimumab) for the Treatment of Inflammatory Diseases in Brazil

Amgen Launches Amgevita (biosimilar, adalimumab) for the Treatment of Inflammatory Diseases in Brazil

Shots:

  • Amgen reports the launch and commercialization of Amgevita, a biosimilar of adalimumab, available in Brazil
  • The ANVISA’s approval is based on the clinical study demonstrating bio-similarity with the reference biological product, via in vitro analyzes, PK & clinical information in patients with moderate to severe psoriasis and RA
  • Amgevita is a fully human IgG1 mAb targeting TNFα, a cytokine which mediates the inflammatory response and has received ANVISA’s approval for RA, PsO, CD, UC, axSpA, HS in Apr’2019

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Behance

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post